NICE Draft Guidance Recommends Less Invasive Capsule Sponge Tests for Oesophageal Cancer Detection

The National Institute for Health and Care Excellence (NICE) has recommended the use of capsule sponge tests—specifically Cytosponge and EndoSign—in draft guidance for patients with persistent gastro-oesophageal reflux disease (GORD).

This less invasive diagnostic tool aims to identify Barrett’s oesophagus and oesophageal cancer, potentially reducing the heavy reliance on traditional hospital-based endoscopies.

Clinical Essentials of the Capsule Sponge Procedure

  • Patient-friendly collection: The test involves swallowing a small capsule containing a sponge that expands in the stomach; it is then retrieved by a thread to collect oesophageal cells for analysis.
  • Primary care accessibility: Unlike traditional endoscopies that require hospital settings and sedation, these tests can be performed by a single clinician in GP surgeries or community diagnostic centres.
  • Triage utility: A positive result on the sponge test acts as a trigger for a confirmatory, diagnostic endoscopy, streamlining the pathway for patients at higher risk.

Draft Guidance Targets Persistent Reflux

NICE released the draft recommendations, the first time a technology has been processed through the National HealthTech Access Programme. Medscape reported that the committee concluded the diagnostic accuracy of these tests is acceptable, with sensitivity for detecting Barrett’s oesophagus ranging between 73% and 80%, and specificity between 92% and 94%.

“As the first technology to be considered through the National HealthTech Access Programme, capsule sponge tests mark an important step in identifying high-impact technologies that, when recommended by NICE, should be adopted consistently across the NHS so patients can benefit wherever they live,” said Professor Jonathan Benger, NICE chief executive.

NICE Draft Guidance Recommends Less Invasive Capsule Sponge Tests for Oesophageal Cancer Detection
Photo: The Economic Times

The recommendation focuses on patients who possess multiple risk factors for Barrett’s oesophagus or oesophageal cancer but do not currently require an urgent cancer referral. As Professor Jonathan Benger, NICE chief executive, noted: “Oesophageal cancer is very difficult to treat when it is diagnosed at a later stage, so identifying people sooner is really important.”

“Capsule sponge tests offer a quick and less invasive way to detect concerning changes associated with oesophageal cancer or Barrett's oesophagus, helping to identify people who should go on to have further tests and treatment,” said Professor Jonathan Benger, NICE chief executive, and explained that these tests offer a way to detect concerning changes, helping to identify those who need further intervention while freeing up endoscopy capacity for higher-priority cases, as reported by the National Health Executive.

Expansion of Community Diagnostic Pilots

While the draft guidance awaits finalization, practical application is already underway through various NHS pilots. Chemist+Druggist reported that Cyted Health, which manages the EndoSign testing, currently has 21 pharmacies participating in north central London and six in the East Midlands.

Data from the pilot, which began in July 2025, shows that 268 patients have been tested to date. The program is set to expand further into Barnet, Haringey, and Islington in January 2027, with a target of reaching 1,360 patients before recruitment closes on June 30, 2027.

pharmacy sign
Photo: Chemist+Druggist
Feature Capsule Sponge Test Traditional Endoscopy
Sedation Required No Yes (Typically)
Location GP/Community Centre Secondary Care/Hospital
Procedure Time ~7 Minutes Longer (Requires prep/recovery)
Primary Role Triage/Surveillance Diagnostic/Biopsy/Therapeutic

Alarm Symptoms That Need Urgent Endoscopy Instead of a Sponge Test

These devices are designed for patients with persistent GORD symptoms, but they are not a universal replacement for standard gastroenterological care. Patients experiencing “alarm features”—such as persistent dysphagia (difficulty swallowing), unexplained weight loss, gastrointestinal bleeding, or iron deficiency anaemia—warrant an urgent referral for direct endoscopic visualization rather than initial screening with a capsule sponge.

Clinical pathways remain essential to ensure that patients with abnormal sponge test results receive timely confirmatory biopsies. Patients should consult their primary care physician to assess their specific risk profile, which includes factors such as age, sex, obesity, and smoking history, before determining if a capsule sponge test is appropriate for their diagnostic pathway.

Capsule Sponge Tests Await Final NHS Guidance Before Routine Use

The transition from draft to routine NHS delivery requires the completion of the ongoing consultation process. Following the anticipated final guidance, the NHS will be required to integrate this technology into clinical pathways.

NICE Draft Guidance Recommends Less Invasive Capsule Sponge Tests for Oesophageal Cancer Detection
Photo: National Health Executive

References

  • National Institute for Health and Care Excellence (NICE). Draft guidance on capsule sponge tests for Barrett’s oesophagus and oesophageal cancer.
  • Fitzgerald RC, et al. “Cytosponge-trefoil factor 3 versus usual care to identify Barrett’s oesophagus in a primary care setting: a multicentre, pragmatic, randomised, controlled, phase 3 trial (BEST3).” The Lancet.
  • As part of the NHS Cancer Programme, the pilot is aimed at people experiencing persistent heartburn or acid reflux. Implementation of diagnostic technologies for early cancer detection.
Photo of author

Priya Deshmukh - Senior Editor, Health

Priya Deshmukh Senior Editor, Health Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.

2027 MLB Hall of Fame Ballot: Buster Posey and Jon Lester Headline Newcomers

Surrey Walmart Parking Lot Shooting: IHIT Investigating Double Homicide